Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Nash Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Nash Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Cell. 2022 Jun 23;185(13):2213-2233.e25. doi: 10.1016/j.cell.2022.05.017.
The impact of apolipoprotein E ε4 (APOE4), the strongest genetic risk factor for Alzheimer's disease (AD), on human brain cellular function remains unclear. Here, we investigated the effects of APOE4 on brain cell types derived from population and isogenic human induced pluripotent stem cells, post-mortem brain, and APOE targeted replacement mice. Population and isogenic models demonstrate that APOE4 local haplotype, rather than a single risk allele, contributes to risk. Global transcriptomic analyses reveal human-specific, APOE4-driven lipid metabolic dysregulation in astrocytes and microglia. APOE4 enhances de novo cholesterol synthesis despite elevated intracellular cholesterol due to lysosomal cholesterol sequestration in astrocytes. Further, matrisome dysregulation is associated with upregulated chemotaxis, glial activation, and lipid biosynthesis in astrocytes co-cultured with neurons, which recapitulates altered astrocyte matrisome signaling in human brain. Thus, APOE4 initiates glia-specific cell and non-cell autonomous dysregulation that may contribute to increased AD risk.
载脂蛋白 E ε4(APOE4)是阿尔茨海默病(AD)最强的遗传风险因素,但其对人类大脑细胞功能的影响仍不清楚。在这里,我们研究了 APOE4 对人群衍生和同基因人诱导多能干细胞、尸检大脑和 APOE 靶向替换小鼠的脑细胞类型的影响。人群和同基因模型表明,APOE4 局部单倍型,而不是单一的风险等位基因,导致风险增加。全转录组分析显示,APOE4 在星形胶质细胞和小胶质细胞中引起人类特有的、由 APOE4 驱动的脂质代谢失调。APOE4 增强了从头胆固醇合成,尽管由于溶酶体胆固醇隔离导致细胞内胆固醇升高。此外,基质失调与星形胶质细胞与神经元共培养时趋化性、神经胶质激活和脂质生物合成的上调有关,这再现了人类大脑中星形胶质细胞基质信号的改变。因此,APOE4 引发了胶质细胞特异性的细胞和非细胞自主失调,这可能导致 AD 风险增加。